Veracyte news

The company is showcasing significant clinical research validation of its Decipher test through multiple presentations at a major medical conference, demonstrating growing adoption and clinical utility in prostate cancer treatment decisions. This represents positive momentum for the company's diagnostic platform and market positioning.

Zacks Rank #1 (Strong Buy) with strong earnings beat of 25.6% in Q2 2026, consistent quarterly outperformance (average 41.8% surprise), and 8.4% estimated earnings growth for 2026.

Zacks Rank #1 (Strong Buy) with strong earnings beat track record (average 41.8% surprise over trailing four quarters). Q2 2026 EPS beat consensus by 25.6% and revenue beat by 4.1%. Estimated 8.4% earnings growth for 2026 demonstrates consistent outperformance.

Veracyte is highlighted as a better-ranked alternative with a Zacks Rank #1 (Strong Buy), strong earnings yield of 4.7%, consistent earnings beats averaging 41.8% surprise, and significant stock outperformance of 35.3% year-to-date.

Veracyte holds a Zacks Rank #1 (Strong Buy) with impressive earnings beat of 25.6% and revenue beat of 4.1% in Q2 2026, plus consistent earnings outperformance with an average surprise of 41.8% over trailing four quarters.

Zacks Rank #1 (Strong Buy) with superior earnings yield (4.7% vs industry -1.4%), consistent earnings beats (41.8% average surprise), and strong stock performance (+28.2% vs industry -3.8%).

Zacks Rank #1 with exceptional earnings beat record (41.8% average surprise across trailing four quarters), Q2 EPS beat of 25.6%, and 8.4% estimated 2026 earnings growth rate indicate strong performance and market position.

Mentioned as a better-ranked alternative stock in the medical space with Zacks Rank #1, but no direct connection to the main news story about Natera's approval.

Zacks Rank #1 (Strong Buy) with strong Q2 2026 earnings beat of 25.6% and revenue beat of 4.1%. Consistent earnings beats in trailing four quarters with average surprise of 41.8% and 8.4% estimated earnings growth for 2026.

Zacks Rank #1 (Strong Buy) with strong earnings yield of 4.7% versus industry's negative 1.4%. Shares up 22.3% with consistent earnings beats averaging 41.8% surprise.

Zacks Rank #1 (Strong Buy) with Q2 adjusted EPS of 54 cents beating consensus by 25.6%, revenues beat by 4.1%, consistent earnings beats with 41.8% average surprise, and 8.4% estimated 2026 earnings growth.

Company beat earnings estimates by 25.6% and revenue estimates by 4.1% in Q2 2026, with strong earnings beat consistency (41.8% average surprise over four quarters) and estimated 2026 earnings growth of 8.4%.

Zacks Rank #1 (Strong Buy) with strong earnings beat of 25.6% above consensus and revenue beat of 4.1%. Consistent earnings outperformance with 41.8% average surprise over trailing four quarters and 8.4% estimated earnings growth for 2026.

Zacks Rank #1 (Strong Buy) with superior earnings yield (4.7% vs industry -1.4%), consistent earnings beats (41.8% average surprise), and strong share performance (+28.2% vs industry +3.8%).

Zacks Rank #1 stock with strong earnings beat (25.6% above consensus) and revenue beat (4.1% above consensus) in Q2 2026, plus consistent earnings beats over trailing four quarters with 41.8% average surprise.

Zacks Rank #1 (Strong Buy) with exceptional performance: Q2 2026 EPS beat estimates by 25.6%, revenues beat by 4.1%. Consistent earnings beats in trailing four quarters with 41.8% average surprise. 8.4% estimated earnings growth rate for 2026.

Strong performance with Zacks Rank #1 (Strong Buy), 28.2% share price gain, 41.8% average earnings surprise, and 4.7% earnings yield above industry average.

Mentioned as a better-ranked alternative in the medical space with Zacks Rank #1 (Strong Buy). Company demonstrated strong earnings beat of 25.6% and revenue beat of 4.1% in Q2 2026, with consistent outperformance over trailing four quarters.

Mentioned as a better-ranked alternative in the medical space with Zacks Rank #1 (Strong Buy). Reported Q2 2026 adjusted EPS of 54 cents, beating estimates by 25.6%, with revenues beating by 4.1%. Shows consistent earnings beat history with 41.8% average surprise over trailing four quarters.

VCYT carries Zacks Rank #1 (Strong Buy) with positive earnings yield of 4.6%, consistent earnings outperformance with 41.8% average surprise, and 38% share price appreciation over the past year.

Company reported strong Q2 2026 results with adjusted EPS of $0.54 beating consensus by 25.6% and revenues of $150.3M beating by 4.1%. Demonstrates consistent earnings beat pattern (4 consecutive quarters, 41.8% average surprise) with 8.4% estimated earnings growth for 2026.